Patient With Stage IV NSCLC and CNS Metastasis With EGFR Exon 18-25 Kinase Domain Duplication With Response to Osimertinib as a First-Line Therapy

JCO Precis Oncol. 2021 Nov:5:88-92. doi: 10.1200/PO.20.00296.

Authors

Jong Taek Kim¹, Wenjuan Zhang¹, Jean Lopategui^{1

2}, Eric Vail^{1

2}, Ani Balmanoukian^{2

3}

Affiliations

¹ Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA.
² Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
³ The Angeles Clinic and Research Institute, Los Angeles, CA.

PMID: 34994592
DOI: 10.1200/PO.20.00296

No abstract available

Publication types

Case Reports

MeSH terms

Acrylamides / therapeutic use*
Aniline Compounds / therapeutic use*
Carcinoma, Non-Small-Cell Lung / diagnostic imaging
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics*
Central Nervous System Neoplasms / diagnostic imaging
Central Nervous System Neoplasms / drug therapy
Central Nervous System Neoplasms / genetics
ErbB Receptors / genetics
Exons
Humans
Lung Neoplasms / diagnostic imaging
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics*
Magnetic Resonance Imaging
Male
Middle Aged
Neoplasm Metastasis / diagnostic imaging
Neoplasm Metastasis / drug therapy
Neoplasm Metastasis / genetics
Neoplasm Staging
Protein Kinase Inhibitors / therapeutic use*
Tomography, X-Ray Computed

Substances

Acrylamides
Aniline Compounds
Protein Kinase Inhibitors
osimertinib
EGFR protein, human
ErbB Receptors